Search
ibalizumab-uiyk (Trogarzo)
Indications:
- multidrug-resistant HIV1 infection (FDA-approved March 2018)
Dosage:
- IV infusion every 14 days
Adverse effects:
- diarrhea, nausea
- rash
- dizziness
- immune reconstitution syndrome
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
antiviral agent
References
Brown T
FDA Approves Ibalizumab for Multidrug-Resistant HIV-1.
Medscape - Mar 06, 2018.
https://www.medscape.com/viewarticle/893512
- FDA News Release. March 6, 2018
FDA approves new HIV treatment for patients who have limited
treatment options.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm599657.htm